R. Katie Kelley, MD

Articles

Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

February 14th 2024

Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.

FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

February 14th 2024

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

Navigating FGFRi Therapy Adverse Effects: Nail Toxicities

February 7th 2024

Experts share preventative and management strategies for nail toxicities and mouth sores that can cause significant quality of life issues for patients being treated with FGFRi.

Monitoring and Managing Hyperphosphatemia

February 7th 2024

Hyperphosphatemia is the most common AE associated with FGFRi treatments and can impact patient quality of life, but there are treatments and possible diet changes that may help mitigate this AE.

Symptoms Associated With Eye-Related Toxicities Amid FGFRi Therapy

January 31st 2024

Ocular toxicities from dry eye to development of cataracts are potential risks with FGFRi treatment; providers share management strategies.

Patient Perspective Regarding FGFRi Adverse Event Profiles

January 31st 2024

A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events.

Common Adverse Events Associated With FGFRi Therapy

January 24th 2024

A review of how frequently adverse events from hyperphosphatemia to nail toxicities to stomatitis and more.

Key Highlights For Patient Education Surrounding FGFR Inhibitors

January 24th 2024

Provider perspectives on the importance of education patients about potential adverse events they may experience when initiating treatment with FGFR inhibitors.

Next-Gen Inhibitors Shaping Cholangiocarcinoma Treatment Landscape

January 18th 2024

Next-generation FGFR inhibitors show promise in early trials evaluating their efficacy and safety for the treatment of cholangiocarcinoma.

First- and Second-Line Treatment Options for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Alterations

January 18th 2024

Experts discuss treatment options for cholangiocarinoma and how FGFR inhibitors have changed the treatment landscape in recent years.

The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

January 10th 2024

Experts in treating cholangiocarcinoma share insights on when biomarker testing is needed and which biomarkers to test for.

Clinical Presentations of Patients With Cholangiocarcinoma

January 10th 2024

Key opinion leaders illustrate how patients with intrahepatic cholangiocarcinoma present in a clinical setting.

Risk Factors Leading to Various Liver Cancers

January 10th 2024

The intricate web of risk factors influencing diverse forms of liver cancers are explored.

Intrahepatic Cholangiocarcinoma Overview

December 14th 2023

Medical experts discuss the pathology of intrahepatic cholangiocarcinoma.

Future of Advanced HCC Treatment

August 22nd 2023

Dr R. Katie Kelley highlights other abstracts presented at World GI 2023 and shares what she looks forward to in the future of advanced hepatocellular carcinoma treatment.

Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC

August 22nd 2023

R. Katie Kelley, MD, comments on the safety and efficacy data from the retrospective analysis of the CELESTIAL study in advanced hepatocellular carcinoma.

The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment

August 18th 2023

Dr R. Katie Kelley explains the design and results of the phase 3 CELESTIAL study investigating single-agent cabozantinib for the treatment of advanced hepatocellular carcinoma.

Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

August 18th 2023

R. Katie Kelley, MD, discusses updated safety data on tremelimumab plus durvalumab for patients with advanced hepatocellular carcinoma.

Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

August 11th 2023

Dr R. Katie Kelley shares her thoughts on the four-year updated survival and efficacy data from the phase 3 HIMALAYA trial in patients with advanced hepatocellular carcinoma.

First-Line Systemic Treatment Options for Patients With Advanced HCC

August 11th 2023

R. Katie Kelley, MD, provides an overview of the first-line systemic treatment options for patients with advanced hepatocellular carcinoma.